CRSPCRISPR Therapeutics AG
$53.41-14% 1Y
$53.41
$44.3452 weeks$76.78
Latest close: back above its 200-day averageOct 9, 2026what changed →
The financials
CRISPR Therapeutics AG by the numbers
Its largest product in Jun 2026 was Collaboration at $10M, 98% of the disclosed total, well ahead of Grant at 1.8%. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
| Product | Revenue | Share |
|---|---|---|
| Collaboration | $10M | 98% |
| Grant | $181K | 1.8% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $10.2M (+598%)
Grant grew -80% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$10.0M$10.0Mquarter on quarter +900%year on year n/a+900%n/a
- Grant$181.0K$181.0Kquarter on quarter -60%year on year -80%-60%-80%
Biotechnology
The closest names by size in the same industry